Hot Features
プレミアム
Teva Pharmaceutical Industries Ltd (TEVA)
NYSE
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
| 日付 | 保有者名 | 取引株数 | 金額レンジ ($) | 取引種別 | 価格レンジ ($) | 届出終了時の株数 | % 変化 |
|---|---|---|---|---|---|---|---|
| 2026-06-18 | Mr. Matthew ShieldsExec. VP of Global Operations | -9.99k | 321.55k | 売り | 32.19 | 0.00 | -100.00% |
| 2026-06-11 | Mr. Eliyahu Sharon KalifExec. VP & CFO | -106.56k | 3.63M | Automatic Disposition | 34.10 | 65.62k | -61.89% |
| 2026-06-05 | Dr. Sol J. BarerIndependent Chairman of the Board | 21.74k | 0.00 | Derivative Exercise and Retained Stock | - | 448.01k | 5.10% |
| 2026-06-05 | Dr. Chen LichtensteinIndependent Director | 14.49k | 0.00 | Derivative Exercise and Retained Stock | - | 19.30k | 301.67% |
| 2026-06-05 | Ms. Rosemary A. CraneIndependent Director | 14.49k | 0.00 | Derivative Exercise and Retained Stock | - | 127.74k | 12.80% |
| 2026-06-05 | Mr. Perry D. NisenIndependent Director | 14.49k | 0.00 | Derivative Exercise and Retained Stock | - | 119.81k | 13.76% |
| 2026-06-05 | Mr. Gerald M. LiebermanIndependent Director | 14.49k | 0.00 | Derivative Exercise and Retained Stock | - | 130.15k | 12.53% |
| 2026-06-05 | Mr. Amir ElsteinIndependent Director | 14.49k | 0.00 | Derivative Exercise and Retained Stock | - | 2.12M | 0.69% |
| 2026-06-05 | Mr. Roberto Agostino MignoneIndependent Director | 14.49k | 0.00 | Derivative Exercise and Retained Stock | - | 119.81k | 13.76% |
| 2026-06-05 | Dr. Tal ZaksIndependent Director | 14.49k | 0.00 | Derivative Exercise and Retained Stock | - | 73.26k | 24.66% |
| 2026-06-05 | Prof. Ronit Satchi-FainaroIndependent Director | 14.49k | 0.00 | Derivative Exercise and Retained Stock | - | 112.40k | 14.80% |
| 2026-06-05 | Mr. Richard D. FrancisPresident, CEO & Director | 6.89k | 0.00 | Derivative Exercise and Retained Stock | - | 1.18M | 0.59% |
| 2026-06-05 | Mr. Richard D. FrancisPresident, CEO & Director | -6.15k | 211.36k | Derivative Exercise and Sale | 34.35 | 1.18M | - |
| 2026-06-03 | Mr. Matthew ShieldsExec. VP of Global Operations | -16.20k | 532.33k | Derivative Exercise and Sale | 32.87 | 9.99k | - |
| 2026-05-14 | Mr. Evan LippmanExec. VP of Business Development | 44.19k | 0.00 | Derivative Exercise and Retained Stock | - | 44.19k | - |
| 2026-05-14 | Mr. Evan LippmanExec. VP of Business Development | -41.66k | 1.48M | Derivative Exercise and Sale | 35.58 | 44.19k | - |
| 2026-05-14 | Mr. Eliyahu Sharon KalifExec. VP & CFO | -153.25k | 5.46M | Automatic Disposition | 35.61 | 172.18k | -47.09% |
| 2026-05-06 | Mr. Amir WeissSenior VP & CAO | -10.68k | 384.44k | 売り | 36.00 | 20.02k | -34.79% |
| 2026-05-05 | Mr. Richard Gordon DaniellExec. VP of European Commercial | -30.00k | 1.06M | 売り | 35.40 | 55.76k | -34.98% |
| 2026-05-01 | Mr. Mark SabagExec. VP of International Markets Commercial | -144.18k | 5.05M | 売り | 34.99 | 80.76k | -64.10% |
| 2026-04-30 | Ms. Christine FoxExec. VP of US Commercial & Head of Innovative Franchise | -21.26k | 750.62k | 売り | 35.31 | 63.65k | -25.04% |
| 2026-03-17 | Mr. Mark SabagExec. VP of International Markets Commercial | -62.10k | 1.87M | 売り | 30.14 | 224.94k | -21.64% |
| 2026-03-05 | Mr. Mark SabagExec. VP of International Markets Commercial | 15.72k | 0.00 | Derivative Exercise and Retained Stock | - | 287.04k | 5.80% |
| 2026-03-05 | Mr. Eliyahu Sharon KalifExec. VP & CFO | 19.92k | 0.00 | Derivative Exercise and Retained Stock | - | 325.44k | 6.52% |
| 2026-03-05 | Mr. Amir WeissSenior VP & CAO | 3.54k | 0.00 | Derivative Exercise and Retained Stock | - | 30.70k | 13.02% |
| 2026-03-05 | Mr. Richard D. FrancisPresident, CEO & Director | 22.43k | 0.00 | Derivative Exercise and Retained Stock | - | 1.17M | 1.95% |
| 2026-03-05 | Mr. Richard D. FrancisPresident, CEO & Director | -20.03k | 634.16k | Derivative Exercise and Sale | 31.67 | 1.17M | - |
| 2026-03-05 | Ms. Christine FoxExec. VP of US Commercial & Head of Innovative Franchise | 9.90k | 0.00 | Derivative Exercise and Retained Stock | - | 84.91k | 13.19% |
| 2026-03-05 | Ms. Christine FoxExec. VP of US Commercial & Head of Innovative Franchise | -7.92k | 250.94k | Derivative Exercise and Sale | 31.67 | 84.91k | - |
| 2026-03-05 | Dr. Eric A. HughesExec. VP of Global R&D and Chief Medical Officer | 10.12k | 0.00 | Derivative Exercise and Retained Stock | - | 107.71k | 10.37% |
| 2026-03-05 | Dr. Eric A. HughesExec. VP of Global R&D and Chief Medical Officer | -9.53k | 301.89k | Derivative Exercise and Sale | 31.67 | 107.71k | - |
| 2026-03-05 | Mr. Richard Gordon DaniellExec. VP of European Commercial | -17.30k | 547.70k | Derivative Exercise and Sale | 31.67 | 85.76k | - |
| 2026-03-05 | Mr. Placid JoverExec. VP & CHRO | -14.15k | 448.11k | Derivative Exercise and Sale | 31.67 | 6.77k | - |
| 2026-03-05 | Mr. Brian SavageInterim Chief Legal Officer | 2.45k | 0.00 | Derivative Exercise and Retained Stock | - | 10.91k | 28.99% |
| 2026-03-05 | Mr. Brian SavageInterim Chief Legal Officer | -1.13k | 35.69k | Derivative Exercise and Sale | 31.67 | 10.91k | - |
| 2026-03-05 | Mr. Matthew ShieldsExec. VP of Global Operations | -17.30k | 547.70k | Derivative Exercise and Sale | 31.67 | 9.99k | - |
| 2026-03-04 | Mr. Richard D. FrancisPresident, CEO & Director | 26.83k | 0.00 | Derivative Exercise and Retained Stock | - | 1.15M | 2.39% |
| 2026-03-04 | Mr. Richard D. FrancisPresident, CEO & Director | -23.39k | 759.44k | Derivative Exercise and Sale | 32.46 | 1.15M | - |
| 2026-03-04 | Mr. Richard Gordon DaniellExec. VP of European Commercial | -53.97k | 1.75M | Derivative Exercise and Sale | 32.46 | 85.76k | - |
| 2026-03-04 | Mr. Richard Gordon DaniellExec. VP of European Commercial | -37.37k | 1.23M | Automatic Disposition | 32.95 | 85.76k | -30.35% |
| 2026-03-04 | Mr. Mark SabagExec. VP of International Markets Commercial | 52.11k | 0.00 | Derivative Exercise and Retained Stock | - | 271.32k | 23.77% |
| 2026-03-04 | Dr. Eric A. HughesExec. VP of Global R&D and Chief Medical Officer | 11.97k | 0.00 | Derivative Exercise and Retained Stock | - | 97.59k | 13.99% |
| 2026-03-04 | Dr. Eric A. HughesExec. VP of Global R&D and Chief Medical Officer | -11.28k | 366.10k | Derivative Exercise and Sale | 32.46 | 97.59k | - |
| 2026-03-04 | Mr. Eliyahu Sharon KalifExec. VP & CFO | 56.76k | 0.00 | Derivative Exercise and Retained Stock | - | 305.52k | 22.82% |
| 2026-03-04 | Ms. Christine FoxExec. VP of US Commercial & Head of Innovative Franchise | 11.36k | 0.00 | Derivative Exercise and Retained Stock | - | 75.01k | 17.85% |
| 2026-03-04 | Ms. Christine FoxExec. VP of US Commercial & Head of Innovative Franchise | -9.10k | 295.36k | Derivative Exercise and Sale | 32.46 | 75.01k | - |
| 2026-03-04 | Mr. Brian SavageInterim Chief Legal Officer | 5.54k | 0.00 | Derivative Exercise and Retained Stock | - | 8.46k | 189.17% |
| 2026-03-04 | Mr. Brian SavageInterim Chief Legal Officer | -2.68k | 86.84k | Derivative Exercise and Sale | 32.46 | 8.46k | - |
| 2026-03-04 | Mr. Amir WeissSenior VP & CAO | 16.33k | 0.00 | Derivative Exercise and Retained Stock | - | 27.16k | 150.79% |
| 2026-03-03 | Mr. Amir WeissSenior VP & CAO | 5.18k | 0.00 | Derivative Exercise and Retained Stock | - | 10.83k | 91.66% |
| 2026-03-03 | Mr. Richard Gordon DaniellExec. VP of European Commercial | 141.48k | 0.00 | Derivative Exercise and Retained Stock | - | 123.13k | -770.96% |
| 2026-03-03 | Mr. Richard Gordon DaniellExec. VP of European Commercial | -62.25k | 2.01M | Derivative Exercise and Sale | 32.36 | 123.13k | - |
| 2026-03-03 | Mr. Richard Gordon DaniellExec. VP of European Commercial | -66.74k | 2.16M | Automatic Disposition | 32.36 | 123.13k | -35.15% |
| 2026-03-03 | Mr. Mark SabagExec. VP of International Markets Commercial | 166.38k | 0.00 | Derivative Exercise and Retained Stock | - | 219.21k | 314.94% |
| 2026-03-03 | Mr. Brian SavageInterim Chief Legal Officer | 2.19k | 0.00 | Derivative Exercise and Retained Stock | - | 2.93k | 295.94% |
| 2026-03-03 | Mr. Brian SavageInterim Chief Legal Officer | -1.27k | 41.23k | Derivative Exercise and Sale | 32.36 | 2.93k | - |
| 2026-03-03 | Mr. Richard D. FrancisPresident, CEO & Director | 515.61k | 0.00 | Derivative Exercise and Retained Stock | - | 1.12M | 85.12% |
| 2026-03-03 | Mr. Richard D. FrancisPresident, CEO & Director | -442.94k | 14.33M | Derivative Exercise and Sale | 32.36 | 1.12M | - |
| 2026-03-03 | Mr. Eliyahu Sharon KalifExec. VP & CFO | 191.28k | 0.00 | Derivative Exercise and Retained Stock | - | 248.76k | 332.78% |
| 2026-03-03 | Dr. Eric A. HughesExec. VP of Global R&D and Chief Medical Officer | 85.62k | 0.00 | Derivative Exercise and Retained Stock | - | 85.62k | - |
| 2026-03-03 | Dr. Eric A. HughesExec. VP of Global R&D and Chief Medical Officer | -80.76k | 2.61M | Derivative Exercise and Sale | 32.36 | 85.62k | - |
| 2026-02-26 | Mr. Eliyahu Sharon KalifExec. VP & CFO | -345.81k | 11.63M | Automatic Disposition | 33.64 | 57.48k | -85.75% |
| 2026-02-15 | Mr. Richard D. FrancisPresident, CEO & Director | 620.11k | 0.00 | Derivative Exercise and Retained Stock | - | 605.77k | -4,324.64% |
| 2026-02-15 | Mr. Richard D. FrancisPresident, CEO & Director | -161.66k | 5.53M | Derivative Exercise and Sale | 34.22 | 605.77k | - |
| 2026-02-15 | Mr. Richard D. FrancisPresident, CEO & Director | -286.12k | 9.79M | Automatic Disposition | 34.22 | 605.77k | -32.08% |
| 2025-12-16 | Mr. Amir WeissSenior VP & CAO | -12.30k | 371.50k | 売り | 30.20 | 5.65k | -68.52% |
| 2025-12-16 | Bridger Management LLC法人 | -77.40k | 2.34M | 売り | 30.24 | 367.60k | -17.39% |
| 2025-12-09 | Mr. Richard Gordon DaniellExec. VP of European Commercial | -115.47k | 1.19M | Derivative Exercise and Sale | 16.99 - 28.68 | 48.38k | - |
| 2025-12-09 | Mr. Mark SabagExec. VP of International Markets Commercial | -118.72k | 1.20M | Derivative Exercise and Sale | 18.61 - 28.75 | 52.83k | - |
| 2025-12-09 | Mr. Mark SabagExec. VP of International Markets Commercial | -98.17k | 2.82M | 売り | 28.70 | 52.83k | -65.01% |
| 2025-12-02 | Dr. Chen LichtensteinIndependent Director | 4.80k | 0.00 | Derivative Exercise and Retained Stock | - | 4.80k | - |
| 2025-11-26 | Bridger Management LLC法人 | -50.00k | 1.30M | 売り | 26.03 | 445.00k | -10.10% |
| 2025-11-20 | Ms. Christine FoxExec. VP of US Commercial & Head of Innovative Franchise | 35.26k | 0.00 | Derivative Exercise and Retained Stock | - | 63.65k | 124.24% |
| 2025-11-20 | Ms. Christine FoxExec. VP of US Commercial & Head of Innovative Franchise | -28.23k | 699.52k | Derivative Exercise and Sale | 24.78 | 63.65k | - |
| 2025-11-14 | Ms. Christine FoxExec. VP of US Commercial & Head of Innovative Franchise | -30.00k | 753.32k | 売り | 25.11 | 28.38k | -51.38% |
| 2025-11-06 | Bridger Management LLC法人 | -200.00k | 4.82M | 売り | 24.11 | 495.00k | -28.78% |
| 2025-11-06 | Mr. Amir WeissSenior VP & CAO | -12.30k | 300.56k | 売り | 24.44 | 17.95k | -40.66% |
| 2025-09-05 | Mr. David R. Mcavoyインサイダー | 1.11k | 20.99k | 買い | 18.86 | 13.03k | 9.34% |
| 2025-08-01 | Mr. Placid JoverExec. VP & CHRO | 6.77k | 0.00 | Derivative Exercise and Retained Stock | - | 6.77k | - |
| 2025-08-01 | Mr. Placid JoverExec. VP & CHRO | -6.05k | 91.75k | Derivative Exercise and Sale | 15.16 | 6.77k | - |
| 2025-08-01 | Dr. Eric A. HughesExec. VP of Global R&D and Chief Medical Officer | -52.74k | 799.44k | Derivative Exercise and Sale | 15.16 | 0.00 | - |
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
メールアドレスで登録
すでにアカウントをお持ちですか？ サインイン
アカウントをお持ちでないですか？ 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。
